Engineered biology is moving from the lab to the centre of the global economy.
Cavano Capital partners with founders whose platforms advance biotech, synthetic biology, clinical development and bio-manufacturing across Europe and Asia.
Most capital treats biotech as a sector. Here it is treated as societal infrastructure. Scientific risk and jurisdictional complexity are underwritten where others see only regulatory friction. We do this because the reward is more than just profit, it is a healthier and brighter future for all.
High-consequence IP at the intersection of clinical evidence and sovereign priorities. The platforms backed here are built to influence reimbursement and access across Health Sciences Authority (HSA) and European Medicines Agency (EMA) markets.
Copenhagen. Singapore.
Cavano Capital operates where the talent is. EMA and HSA pipelines are diverging as Asia accelerates trials and Europe tightens reimbursement standards. The result is a dual-jurisdiction bridge that allows founders to scale without borders.